Conversation with Merlin [email protected] · Sun Dec 17 2023

Prepare 2 alert cards for any high risk medications

When preparing alert cards for high-risk medications, the most important elements to include are the medication name, dosage, purpose, potential risks, necessary precautions, and what action to take in case of an adverse reaction or overdose. Here are two examples of alert cards for hypothetical high-risk medications:

Alert Card for Medication A: Warfarin (Coumadin)

Medication: Warfarin (Brand name: Coumadin) Dosage:** [Patient-specific dosage] — Taken [Patient-specific frequency]

Purpose: Anticoagulant used to prevent blood clots.

Potential Ris:

  • Bleeding complications.
  • Drug and food interactions (e.g., with alcohol, certain medications, cranberry juice, and foods high in vitamin K).

Precautions:

  • Monitor IN/PT regularly to ensure therapeutic levels.
  • Wear a medical alert bracelet indicating you are on Warfarin.
  • Keep a consistent vitamin intake in your diet.
  • Consult with a healthcare provider before starting or stopping any medications, including over-the-counter drugs and herbal supplements.

In Case of an Adverse Reaction:

  • If minor bleeding occurssuch as a nosebleed), apply pressure and call your healthcare provider.
  • In the case of significant bleeding or an injury, seek emergency medical attention immediately.
  • Report any signs of unusual bruising, blood in urine/stool, or severe headache to your doctor.

Alert Card for Medication B:ulin (e.g., Lantus)

Med Name: Insulin Glargine (Brand name: Lantus) Dos: [Patient-specific dosage] — Administered [Patient-specific frequency]

Purpose: To manage blood glucose levels in patients with diabetes.

Potential Risks:

  • Hypoglycemia (low blood sugar levels).
  • Hyperglycemia ( blood sugar levels if insulin is underdosed).
  • Lipystrophy at injection sites.

Precautions:

  • Monitor blood glucose levels regularly.
  • Always carry a source of fast-acting sugar for hypoglycemia episodes (e.g., glucose tablets).
  • Rotate injection sites to prevent skin changes.
  • Do not share insulin pens, cartridges, or syringes.

In Case of an Adverse Reaction:

  • If signs of hypoglycemia occur (confusion, shaking, sweating), consume fast-acting sugar and recheck blood sugar in 15 minutes.
  • Ifoglycemia is severe or persistent, seek immediate medical help or have someone administer glucagon if available and trained.
  • If hyperglycemia is suspected, check blood sugar levels, follow the high blood sugar protocol as advised by your healthcare provider, or seek medical attention.

Note: The details on the dosage and frequency are kept vague [Patient-specific dosage/frequency] and should be personalized based on the individual's prescription and healthcare provider's advice.

2 more medications

Certainly, here are alert cards for two additional high-risk medications:

**Alert Card for Medication C: Digoxin (Lanoxin

Medication Name: Digoxin (Brand name: Lanoxin) **Dosage [Patient-specific dosage] — Taken [Patient-specific frequency]

Purpose: To treat heart failure and irregular heartbeats (arrhythmias).

**Potential Risks:- Digoxin toxicity can occur easily due to its narrow therapeutic index.

  • Electrolyte imbalances (especially low potassium or magnesium) increase toxicity risk.
  • Interactions with other drugs can alter digoxin levels.

Precautions: -ly monitor serum digoxin levels, kidney function, and electrolytes.

  • Inform healthcare providers of all other medications you are taking.
  • Do not take OTC medications, especially antacids or laxatives, without consulting your doctor.
  • Report any signs of digoxin toxicity immediately: gastrointestinal (nausea, vomiting, diarrhea), blurred vision, seeing halos, confusion, and irregular heartbeats.

In Case of an Adverse Reaction:**

  • Contact your if you experience any symptoms of toxicity.
  • In case of suspected overdose, seek immediate emergency medical attention.

Alert Card for Medication D: Methotrexate (Trexall)

Medication: Methotrexate (Brand name: Trexall) **Dosage:**Patient-specific dosage] — Administered [Patient-specific frequency]

Purpose: To treat certain types of cancer, severe psoriasis, and rheumatoid arthritis.

Potential Risks:

  • Myelosup (which can lead to low blood cell counts and increase infection risk).
  • Hepatotoxicity (liver damage).
  • Renal toxicity (kidney damage).
  • Mucitis and gastrointestinal ulceration.

Precautions:

  • Regularly monitor blood and liver function tests.
  • Stay hydrated to help prevent renal.
  • Avoid alcohol to decrease the risk of liver toxicity.
  • Use reliable birth control as methotrexate is teratogenic (can harm an unborn baby).

In Case of an Adverse Reaction:

  • For signs of infectionfever, chills, sore throat), immediately report to your healthcare provider.
  • If experiencing unusual bleeding, bruising, or signs of liver toxicity (yellowing of the skin or eyes, urine), seek medical help.
  • Follow up with your doctor for any new mouth sores, abdominal pain, or black/tarry.

It is crucial that the dosage and frequency details be tailored to the individual's prescription and in accordance with the guidance from their healthcare provider

Prepare 2 alert cards for any high risk medications

Alert Card for Medication E: Lithium (Lithid)

Medication: Lithium (Brand name: Lithobid) Dosage: [-specific dosage] — Taken [Patient-specific frequency]

Purpose: To treat and prevent episodes of mania in patients with bipolar disorder.

Potential Risks:

  • Lithium toxicity which can occur at doses close to therapeutic levels.
  • Dehydration and renal function impairment.
  • Thyroid abnormalities, including hypothyroidism.

Precautions:

  • Maintain adequate fluid intake and a salt intake to prevent dehydration.
  • Regularly monitor kidney and thyroid function, as well as lithium blood levels.
  • Avoid non-ster anti-inflammatory drugs (NSAIDs) and diuretics which can increase lithium levels.
  • Inform healthcare providers you're taking lithium before any surgery or new drug prescription.

**In Case of an Adverse Reaction:- Early signs of toxicity include nausea, vomiting, diarrhea, tremors, confusion, or atax. If these occur, contact your healthcare provider immediately.

  • If severe symptoms such as extreme thirst, frequent urination, or severe tremors occur, seek emergency medical treatment.

**Alert Card for Medication F: Clozapine (Clozaril)**Medication: Clozapine (Brand name: Clozaril) Dosage: [Patient dosage] — Taken [Patient-specific frequency]

Purpose: manage symptoms of schizophrenia in patients unresponsive to other treatments.

Potential Risks:

  • Agranulocosis (a severe decrease in the number of white blood cells).
  • Seizures, myocarditis (inflammation of the heart muscle), and cardiomyopathy. Increased risk of developing metabolic syndrome (weight gain, dyslipidemia, hyperglycemia).

Precautions:

  • Weekly blood tests for first 6 months to monitor white blood cell counts, then less frequently as prescribed.
  • Be aware of signs of infection such as fever or sore throat, and seek immediate medical attention.
  • Regular monitoring of weight, lipids, and glucose levels.
  • Do not abruptly stop taking cloine as withdrawal symptoms can occur.

In Case of an Adverse Reaction:

  • If you symptoms such as fever, flu-like symptoms, or sore throat, your healthcare provider immediately due to the risk of agranulytosis.
  • For new-onset seizures, chest pain, or significant changes in heart rhythm, obtain urgent medical care.

For both medications, ensure that the and administration frequency are clearly specified based on the patient's individual treatment plan The healthcare provider should provide these specifics.

%PDF-1.4 % 9 0 obj <> endobj 37 0 obj <>/Filter/FlateDecode/ID[<511D81E4C823079F14A719C2AEE68921><940396CC49DB344DBB373A7EAC1C47A0>]/Index[9 120]/Info 8 0 R/Length 123/Prev 61533/Root 10 0 R/Size 129/Type/XRef/W[1 2 1]>>stream hbbd``b`I@UH @[ H8$~ 6.a$xfnH0X@RObA6 b L 3@b %3]X` endstream endobj startxref 0 %%EOF 128 0 obj <>stream hb``b``c[N Y8!O8`SxKlIlhGe!0nZ !|,P endstream endobj 10 0 obj <> endobj 11 0 obj <>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC]/Properties<>/Shading<>/XObject<>>>/Rotate 0/TrimBox[0 0 612 792]/Type/Page/u2pMat[1 0 0 -1 0 792]/xb1 0/xb2 612/xt1 0/xt2 612/yb1 0/yb2 792/yt1 0/yt2 792>> endobj 12 0 obj <>stream hXio8O!_fpA>;>3Ln,JrWnh{~ V&Yu*R2BSw('<^ ]:P7^x"^hB/L"/BH``L (L\aCb uvAx VD:0+lCY)ts /d>`,09R@%/rb4cPi&!QM;Bfb^ hEZ>G'@ sZS:zraKa3t1q\IvwG:]Y~~X'AZ]EyW4*xo- 3aa *o!2:w>LO$,(ChzT0[:E%TqNRImi$FZNW_6rs%"/iqIzqaKm5T-!6E+eMIU2b*jisIUYR-[j7]-Y'S iD >A Sd_=}e2dkPoU4YKZRJOTE%UT5}BX:gCTl?Mdi$K]+ y=_f UlD{& \E.6hr:<*i=9IefimF85*U]U44:dF|>;}|>ya.W4i_^V3xsW c8acO'Ts8\3N[qO'8uyn f>=3+srks6Dqf U[s |6 ~zI~GE_JTB^S4W5wpq+=EL i:n- -mQ-(QLyy}mh@>@rLc-]tx%yY?uxX{27| xwunGSO}8 wNcCw 4Tqv]cJF7'Nq/Y_1iY +rWp%Y'Z;t2um3Ny3meN-yY_0Y w@n 'l}ATqf=s);~:CxZ/Z667|{XM}g2Ll|jE^*wGh5krq/`/ endstream endobj 13 0 obj <>stream HWMsFWL%v?` kUIQR;*?3Zi!V7=sy}.z+lR^_Z L7s*)H_MggZ'3qa:.f2 CvK*SW:jru\M92W= 3P/QGYNjJG2KU.Vk%2a\]7&rL&!d |h*6dz6XgE{ZB?wUI 6V \R$N:E&n qlSmN yb(jb0SRRkZ_Pz4Mkt=D7HR/\]18?4Z(qj,2'7M4+n+.y=kkBHqywr7;YT[@|39[v^`R^L(Ve nZFdJ[)wg3b0)4?b@<i_@gF'Z1 sHk]&$Tk\/ KbEq4j,* e8s+}jir$aUV$SPOfR XF4z:kS o,ux|bR*GdbvX" 1:M+q>G8yX'KGE819sF1<+}Pa&0oPm'S <&mF9 Grq}1OFI`E0GNI3sx#'~ K8)}N~$_SNA<]d1a\M~}|H~zeiUz4c?r,YE?V76U}7`p$ c |pLC`08!j#"ib`S D=QXT(iS1 w9p~O%L{"L6DQJs5Camts/&ZwU[i_ 3Ys;PI7T)1/g4VV;Cyys.6_Z|q_Q|_w!abMjn YNmZ8oeoeoe-p-={-OeOY [a` [n`i 97T*JL(;H`j7 a4+; ky|\4VHF%]&w2DT+81<7!<+mp<:ODX=&}&pNG:r?Cz~,{YzmRw7,u<^:OqUJ|7 *? q2a]v;{>8uW<-a_ % &p}T'p!P:Q;04Yo-UY#'TQc|wt.qR ;& K*1cscpH'8Ta5xFtk<q8.5p? P*Tz`|bPq->}$,~|FEQIk~0r"*yjBF 9py2e|qC@+p z_RAutc$;5)Z 8e>q4Ojz@l\!, Rd}"`\R endstream endobj 14 0 obj <>stream HWn}h /Tvw&p`4 p9=;C2zluu]N]A=wUwq^zw/FXeok[U-YWcUWYSuOW[VzuBEWrhK'>Ql_-qYQ>2S#'v#G}ov.Eb. K'<<]#W+Wc<q`]1s-l+8)X{vM9kjdw5~4d\.nz/?N~4g87Zd$$WhW\$q$A"WPM'AY.w?.A%1jr<"j(|_ @* c0'b?es'k#;=*sb^rkk67 hjhc:k?Xb9g{= 0r7hk-:kR_s6."(<42 8 S"r]M>*Djp- g gi\5%HOi%2@$hETR.'d/RN!\I$%!24 8 ?/^!G| ( <LC. H up9#Z@z_\Sb6#D 803)66+B%K,Zj/C! 5c sEX[B LZ!9SD@1DXb*X$Q Aw@G%3sMg)Q=%F4NtR#J5xSKPY!d)U8[#*(](x)Nm@W JRPKsYAqFQ]`KCUyAP;Qh3:%20".Bkf VlC19W6^F bd_&Apa ;$D>EMD28+<#l EQ dB)=ID D`#qP(H Aq-c"I#%ic Hvl`b p4k"b U+CD H-oNBBZUN{*.2{+Q[;+7Vo&O_w^mil}7ZIb;4Pl3| $iKX[[Kp b CdZ4)nQZ2#"J )4^+0&]VpVg`d&0tJg?Xnn@q Bu%6@*AB!y <\ine/pZ%CG[_am|+nr[$3n[8J F1Xb9mis%L,TOqHMk"1~~rY#D IP&Lm )>92}tI (*qs.@$$ j"EsTm"g-\J[\/}dw3= X_dQpK]kGHy6i\3|mk_"t8AQ4fa T3^9MHera"t ;Y)O-K9BTmF;\J+\/eja<0u^TrsEw[Tm#;2?lJrBTz,r<>>Q8P/.lm2pV.owFD3\ #FKU6.UY;:9Q7g0x6[fU\O4]XjQxf*tEnz ?Y\u C_S `![t3|dV|o-|:s6TVdUFezXDS-}T4b,c]5$|3|y4f}|nomKqM{! ^)e z nj3l,}Gcmt ?`]T.H6G&.{|W;#L}0?'9WI [b:wo<DZ:oYzOUhPz6OaB.p uKJ'{}Q/}m(-6C6WIz\!1CPD[C px#N ctkN*SB][Bw${M^(TuUaXEQ<Fq-US]`bI[u!R44'N+*,T T+I O$q+K`<"MJM(t N7Evz[ % endstream endobj 15 0 obj <>stream HnP}H)bO]!V]wG mGD^[qE[-W+Wlb:<'| ez+8]{Le?m{?PF%Z_;muN}}W[ ?85 [.s?[mIFO5mYp $` " *U !U,k_lmKYHHj;|z&h<iyrs-E" e6,btX8n1AM9e0

ismp.org

%PDF-1.5 % 7 0 obj <> endobj xref 7 31 0000000016 00000 n 0000001106 00000 n 0000000916 00000 n 0000001165 00000 n 0000001384 00000 n 0000001531 00000 n 0000001657 00000 n 0000001798 00000 n 0000001980 00000 n 0000002574 00000 n 0000003164 00000 n 0000003198 00000 n 0000003915 00000 n 0000004644 00000 n 0000005335 00000 n 0000005871 00000 n 0000006559 00000 n 0000007448 00000 n 0000008074 00000 n 0000008923 00000 n 0000009827 00000 n 0000012519 00000 n 0000018223 00000 n 0000018762 00000 n 0000022060 00000 n 0000022428 00000 n 0000031057 00000 n 0000031564 00000 n 0000047604 00000 n 0000048881 00000 n 0000050347 00000 n trailer <<16cf372f0655604db4cad84314dca7fc>]>> startxref 0 %%EOF 9 0 obj<>stream xb``a``>P30p4 GJ |LOh,qeaZ0Yw2 "/R%1AAG\aG @7p endstream endobj 8 0 obj<> endobj 10 0 obj<> endobj 11 0 obj<>>> endobj 12 0 obj<>>> endobj 13 0 obj<>>> endobj 14 0 obj<>/Font<>/XObject<>/ProcSet[/PDF/Text/ImageC]/ExtGState<>>> endobj 15 0 obj<> endobj 16 0 obj<> endobj 17 0 obj[/ICCBased 27 0 R] endobj 18 0 obj<>stream HMo@s$<^K*R5RQ" `*~]OEk3;T) IMuU{V`8j=M[\$OBytA[8@w:XMXH#b 'w8vXYXlBvCb#MWre| G8TV8zG>^"lt$r|Cq@ f$yhbl2GtbG{Et{'~kzT 5 Ow]i^QcS%(Gk-wv34gt<@t1I\n~t50&l{G ;1b: Rt]}vT,T*hTWh[siTGnN<1^\^lR/2#U>3I7` X>~~/>Mxd:6 8 6h]d\8s]28~ ==X#dCzI HnIY`4/HjA4}`v endstream endobj 19 0 obj<>stream HT] }W *JiTFi 2EwfgDs9e( UNS4&9feXaR.XRKdtQ3D #+1-i'!;$'e48x4H/C<_Outa.P;$X3B7(Y&a|0o0V[Cs-yN d3JO#g?H!Mn)3-;=?/Pk)PQ+B /Zu/B[0RR]0).uWQ/a?jIPN[T8=hla hO1)ZphFxPsB+\:M FA; zdZ(;J;_BA\hYPKcrbL=}B`^?P>dSHQ\N^|>A)U?7i3k1L+R}IV VNIp V4y9q~e6PA.'&yE'0 "&8[U.x\ K@ endstream endobj 20 0 obj<>stream Hn0yAnXzel7ce9Nt@h(Q?0fwTSQp<TYOiQ&z}-&? W==_ Q.+k0Ko"m Wh/QEUFmIRwj9fevU" b6?j#r+_Q$*(kR_Pvc!?aN"hS4 ZxRswB-CZETtx{qn.SrQCT)gTCD(tmdFi8/TPsv|3)7?RtO\geq6( x+8=~?; endstream endobj 21 0 obj<> endobj 22 0 obj<>stream Hn0y9&O(jdI&U_'fU[*JlVq<7gmfP+F^s 4R@;e *v3.2GoC9pQ]N^ ]l[Wb*. tsV5j\IAVDeI4G.E$.( 67)8>=X dwJP9VFA7T{yJT7e%uq/=R ^4 BY= :-Pgq~O~YS"yEv NT B$O# 2+]"R?\#R Pn#!dO#pB~=SVZ#O6 O;(@=o~(Ow%7n3v;\'E`GrF$V)2^A8c'1Faz( Z} 6g=XnvcAL\CNSH;CyR9H ]M38%EOwqX(9 0[XKJ B5e0!W\Oz endstream endobj 23 0 obj<>stream H6z>) w2erKT!DDx@nr=w7llJNn ~DvO@s5 Ug ^82/ I_gz;YShf "RJJ:ONR#O[ aAbw$ 7c/'x .*YBKAVXRW]$ u@r 'AN5cu'GqN"r8M^i*Y?F7$7I(ON(.XKKo|uTR\V 7Ab:&$[F;'lqv5G.BYh'fe1O}kg{ zG{L8(|z Ic1uPAc4 7;4p|*yK'^ON[Hm2e9/6yq|+BqhW;$uxJ~iSd9k fuYC^e,*mNoop583^t@\oUWit2LDM= _ endstream endobj 24 0 obj<>stream HK0AJf+bCYm}IE/IiK{% +8H.6(cDQ Cc lg%0U (j40f Yu& A]\+yuFALtV[0~(dxx,J6b %y2?GTj.A?KK}\V1| SF%2#vqC2yC`D|4bAKEuaHT %% &aw6_8Br ,q>SCI-zwPjJ_PNB`s9@3Q CUinFjf4;^*e|6Mo|J~}|qY]IT;~vqk>4z=w0W 6K~ INh"cE/*`w($-)&fk!;J)tS8 endstream endobj 25 0 obj<>stream HTK8+@8)eHrrpCA{0g{ "s4U.qqC=H<2q,/ Kn1<X%kWo 1"JJ`iK0x/D1K@Ymo*G,!%YH^ G'uPZ&V^&LX%K6$VXEEq\ 6F@2As6` 3~n'06ma9U$dTCKUp0GFpzh~j@T/gb^4@ O VLZ,ff\pG:jaq(G*L } cfKvR3=ewEp70xh>XrOzk5|=iCEAyPpvAC~?fW]]3K BFv++Yl% xBMXBYMM_d@ 4z F^d (!N! H{0H]ACMSr CPmA/>pj 4p_n:mywV4+fp<]xZ"mnjot=9z"/Hr|HhJQKp\,+}&>stream H|Tr8+V-8Ub@Q-> hV~#YN9$8M$RNO5J-jrS~}Fonn#)SSAsI )6^ChUje}F UXE(CRi"!:g"|m)'*r `@%R4'4} =K4B\Z,*eBsM kppe|\*Me ]/)kZuM3*=&ad; qS Dei/ ,|; Bn0:U[8S0@D0l# U>G | {P'vyZODq/siq,EdrIm{M\440 ^>lb /RR{8al5P BEOicFShvH2[T/f%HlZlq!z;'=?U"^E@k*SgCKI~~)WAg W APPu\4-zM*Knf]Nn%qr!5\ -PN>4=}Q~vlf~ p? l~CGLZP'Sl{JYZ]H3)m=vyMU=Ekz h WcHlX8y&faXRQ!'fE}e% endstream endobj 27 0 obj<>stream hwTTwz0z.0. Qf Ml@DEHb!(`HPb0dFJ|yygs{.$O./ 'z8WGx0YA@$/7z HeOOT_lN:K"N3"$F/

nursingworld.org

A PINCH While the medicines identified as high-risk may vary between hospitals and clinical units depending on the types of medicines used and patients treated, analysis of incident data and review of the published literature identified a group of medicines that should universally be considered as high-risk. These medicines include anti-infective agents, anti-psychotics, potassium, insulin, narcotics and sedative agents, chemotherapy and heparin and other anticoagulants. These medicines are represented by the acronym 'A PINCH'.The poster below can be used to assist hospitals in raising awareness of A PINCH medicines.High-Risk Medicines A PINCH PosterTo assist hospitals in monitoring risks associated with high-risk medicines, the tool below can also be used to monitor local implementation and compliance with the NSW Health High-Risk Medicines Management Policy (PD2020_045).High-Risk Medicines Management Implementation Checklist'A PINCH' TableThe table below provides:Examples of high-risk medicinesLinks to information and recommendations for specific drugs covered by A PINCH.Links to selected clinical indicators from the National Quality Use of Medicines in Australian Hospitals (QUM Indicators) to support hospitals in the monitoring of high-risk medicines use.High-Risk Medicine GroupsExamples of medicinesLink to informationLink to QUM IndicatorsA: Anti-infective Amphotericin Aminoglycosides Non-lipid and lipid formulations of injectable amphotericin (NPSA-UK) 2.3-Duration of empirical aminoglycoside therapy P: Potassium and other electrolytes Injections of potassium, magnesium, calcium, hypertonic sodium chloride High-Risk Medicine Management Policy Directive Potassium (Intravenous) Standard (NSW Health) 6.1-Potassium ampoule storage outside pharmacy I: Insulin All insulins Safe Administration of Medication Pen Devices (Clinical Excellence Commission) Know your insulins - Poster (NSW Therapeutic Advisory Group) Nil N: Narcotics (opioids) and other sedatives Hydromorphone, oxycodone, morphine fentanyl, alfentanil, remifentanil and analgesic patches, Benzodiazepines, for example, diazepam, midazolam. Thiopentone, propofol and other short term anaesthetics High-Risk Medicine Management Policy Directive Hydromorphone Standard (NSW Health)Opioid Skin Patches are High Risk Medicines(NSW Therapeutic Advisory Group) Quick Steps through Opioid Management (Agency for Clinical Innovation) Safe Use of Fentanyl Skin Patches (NSW Health) 4.1-Documentation of pain intensity4.2-Pain management plan at discharge 5.7-Sedatives at discharge 6.3-Parenteral pethidine C: Chemotherapeutic agents Vincristine Methotrexate Etoposide Azathioprine High-Risk Medicine Management Policy Directive Vincristine Standard(NSW Health) 3.6-Protocol based chemotherapy H: Heparin and anticoagulants warfarin enoxaparin rivaroxaban dabigatranapixaban High-Risk Medicine Management Policy Directive Anticoagulant Standard (NSW Health)Intravenous Unfractionated Heparin Recommended Standard (Clinical Excellence Commission)NOAC Guidelines (Clinical Excellence Commission)Perioperative Management of Anticoagulant and Antiplatelet Agents (Clinical Excellence Commission) 1.3-Enoxaparin dosing1.4-Warfarin initiation1.5-Warfarin dose review 1.6-AF patients discharge on anticoagulant5.4-Warfarin written information Other High-risk medicines identified at Local Health District/ Facility/Unit level which do not fit the above categories. High-Risk Medicine Management Policy Directive Paracetamol Standard (NSW Health)NOAC Guidelines (Clinical Excellence Commission) Examples of dose specific safety measuresTransdermal patches:Confirmation from the prescriber should be sought if multiple patches are to be applied.The time of application, site of application and time of removal should be documented on the medication chart.Transdermal patches should not be exposed to extremes of temperature.Transdermal patches should not be cut.Transdermal patches containing opioids should be securely disp

cec.health.nsw.gov.au